`
`A0 12(2- (Rev. 08/10)
`
`TO :
`
`1111111 Step 3
`Director ei‘the H.231 Patent and Trademark Office
`Poi}. Box 1451.3
`Aiexandria, VA 2231341159
`
`TRADEMARK
`
`1112130111“ 0N 11111:
`FILING 0R DETERMINATIGN OF AN
`ACTIGN REGARDING A PATENT (IR
`
`in Campiianee with 35 USC. § 290 and/er 15 U.S.C. § 1116 you are hereby advised that 31 601111 action has been
`
`10111163 District 01 Deiawa re
`
`’11edinthe US. D1str1ct Court
`
`01] the feliewiiig
`
`E] 'E‘i‘ademarks (11'
`
`Mi’ziteths.
`
`( Z the patent ache-11 involves 35 USE. § 292.):
`
`DOCKET NO.
`
`DATE FILED
`
`US. DISTRICT COURT
`
`PLAINTIFF
`TEVA PHARMACEUTICALS ENTERNATEONAL GMBH,
`e1 1311.
`
`3
`
`DEFENDANI
`MYLAN LABORATORIES LEMETED
`
`13/12/2917
`
`.
`
`forthe District of Deiaware
`
`PATENT OR
`TRADEMARK NO
`
`DATE OF PATENT
`OR TRADEMARK
`
`,
`r
`.
`,‘ T ,_ T
`W
`1,
`,
`“KERR 0L P53“ OR TRAJEM‘
`
`«121"
`
`1 US 8,599 707 B2
`
`12/1 "Ii/2013
`
`Eagie Pharmaceuticaie, inc.
`
`2 US 8 791,270 82
`
`7/29/2014
`
`Cephaion, fine.
`
`3 US 9,000,021 B2
`
`4/7/2015
`
`Eagie Pharmaceutieais, inc.
`
`4 US 9,034,908 BE
`
`5/19/2015
`
`Eagie Pharmaceutieais, inc.
`
`5 US 9,144,568 B1
`
`9/29/2915
`
`Eagie Pharmaceutieais, inc.
`
`DATE INCLUDED
`
`In the above—entitled case, the following pate11t(s)/ trademarfls) have been inniuded:
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`: Amehdment
`DATE OF FATE NT
`OR TRADEMARK
`
`[3 Answer
`
`[1 Cress; Bill
`
`[:1 Other Pieaehhg
`
`Y
`
`$7
`
`17
`
`\T‘J‘
`
`.
`
`r
`
`1 ARI”
`
`
`AOLDuR 0L Ph‘ERT OR TRA‘JEM‘
`(BY) DEPUTY CLERK
`
`[11 the abeve -----eht1tied case, the feiiewiiig deciswn has been rehdered erjudgement issued:
`DECISION/JUDG EEIENT
`
`Copy Inn-Upon initiation (11" action, maii this copy to Director Cepy 3------ Igioh termination of aei'ien, mzaii this (:(ipy te Iiirecthr
`Copy 2------Upon filing decoment adding patenfls), maii this ehpy th Director Cepy 1------Cause fiie (:(ipy
`
`
`
`Case 1:17-cv-01790-GMS Document 4 Filed 12/12/17 Page 2 of 3 PagelD #: 231
`
`A0 12(2- (Rev. 08/10)
`
`TO :
`
`111111151911 3
`Director ei‘the H.231 Patent and Trademark Office
`Poi}. Box 1451.3
`Aiexandrie, VA 22313411511
`
`TRADEMARK
`
`1112130111“ 0N 11111:
`FILING 0R DETERMINATIGN OF AN
`ACTIGN REGARDING A PATENT (IR
`
`in Campiianee with 35 USC. § 291'} and/er 15 U.S.C. § 1116 you are hereby advised that a unit action has been
`
`10111163 {31511161 01 Deiawa re
`
`’11edinthe US. D1str1ct Court
`
`01] the feliewiiig
`
`E] 'E‘i'ademarks (11'
`
`5513211621115.
`
`( Z the patent ache-11 involves 35 USE. § 292.):
`
`DOCKET NO.
`
`DATE FILED
`
`US. DISTRICT COURT
`
`PLAINTIFF
`TEVA PHARMACEUTICALS ENTERNATEONAL GMBH,
`e1 1311.
`
`3
`
`DEFENDANI
`MYLAN LABORATORIES LEMETED
`
`13/12/2917
`
`.
`
`forthe Dis1rie1 of Deiaware
`
`PATENT OR
`TRADEMARK NO
`
`DATE OF PATENT
`OR TRADEMARK
`
`‘
`r
`.
`,‘ T M T
`W
`W
`1
`“KERR 01 P53“ OR TRAJEM‘
`
`«121"
`
`1 US 9,265 831 B2
`
`2/23/2016
`
`Eagie Pharmaceuticaie, inc.
`
`2 US 9 572,296 82
`
`2/21/2017
`
`Eagle Pharmaceuiieais, inc.
`
`3 US 9,5?2,797 B2
`
`2/21/2917
`
`Eagie Pharmaceutieais, inc.
`
`4 US 9,572,881” B2
`
`2/21/2017
`
`Eagie Pharmaceutieais, inc.
`
`5 US 9,5?9,384 B2
`
`2/28/2917
`
`Eagie Pharmaceutieais, inc.
`
`DATE INCLUDED
`
`In the above—entitled case, the following pate11t(s),/’ trademarfls) have been inniuded:
`INCLUDED BY
`
`PATENT OR
`TRADEMARK NO.
`
`: Amehdment
`DATE OF FATE NT
`OR TRADEMARK
`
`[3 Answer
`
`[1 Cress; Bill
`
`[:1 Other Pieaehhg
`
`Y
`
`$7
`
`17
`
`\T‘J‘
`
`.
`
`r
`
`1 ARI”
`
`
`AOLDuR 0L Ph‘ERT OR TRA‘JEM‘
`(BY) DEPUTY CLERK
`
`[11 the abeve -----emfiied case, the feiiewiiig deeiswn has been rehdered erjudgement issued:
`DECISION/JUDG EEIENT
`
`Copy Inn-Upon initiation (11" action, maii this copy to Director Cepy 3------ Igzoh termination of aei'ien, mzaii this cepy te Iiirecthr
`Copy 2------Upon filing decoment adding patenfls), maii this ehpy th Director Cepy '1------Cause fiie cepy
`
`
`
`Case 1:17-cv-01790-GMS Document 4 Filed 12/12/17 Page 3 of 3 PagelD #: 232
`
`A0 12(2- (Rev. 08/10)
`
`TO :
`
`111111511111 3
`Director 611111: US. P1119111 and Trademark Office
`I919. Box 1451.3
`AIexamIrie, VA 2231343159
`
`TRADEMARK
`
`1112130111“ (IN 11111:
`FILING 0R DETERMINATIGN OF AN
`ACTIGN REGARDING A PATENT (IR
`
`E11 Cemplianee with 35 USC § 290 and/er 15 U.S.C. § 1116 you are hereby advised that 31 601111 action has been
`
`10111163 District 01 Deiaware
`
`diedin 1he'J. SD1S1.1czt C011r1
`
`011 the fellewiilg
`
`E] 'E‘i‘adeanatks (11'
`
`MPaiems.
`
`( Z the patent ache-11 involves 35 USE; § 292.):
`
`DQCKET N0.
`
`DATE FILED
`
`US. DISTRICT COURT
`
`PLAINTIFF
`
`12/12/2017
`
`.
`
`DEFENDANT
`
`forthe DisIrieI of Deiaware
`
`TEVA PHARMACEUTICALS ENTERNATEONAL GMBH,
`e1 :11.
`
`3
`
`MYLAN LABORATORIES LIMITED
`
`PATENT OR
`TRADEMARK NO
`
`DATE OF PATENT
`OR TRADEMARK
`
`,
`r
`,
`,‘ T ,_ ,
`W
`W
`,
`“KERR 0L P53“ OR TRMEM‘
`
`«121'
`
`1 US 9,597,397 B2
`
`3/21/2017
`
`Eagie Pharmaceuticaie, inc.
`
`2 US 9 597, 398 82
`
`13/21/2017
`
`Eagle Pharmaceuticaie, fine.
`
`US 9 ,597’ ,399 82
`
`3/21/2917
`
`Eagie Pharmaceutieais inc
`AOLDuR 0L PHAERT OR TRA‘JEMARR
`(BY) DEPUTY CLERK
`
`DATE INCLUDED
`
`In the above—entitled case, 111:? following pate111{s)/'11ademrk(s) have been inniuded:
`INCLUDED BY
`
`PA’I‘BNT OR
`TRADEMARK NO.
`
`: Amehdment
`DATE OF FATE NT
`OR TRADEMARK
`
`[3 Answer
`1
`
`$7
`
`[1 Cress; Bill
`17
`‘\ T 1 , T‘
`
`[:1 O1herPieaei1hg
`r
`1
`‘\
`1"
`
`1
`
`[11 the abeve -----e111111ed case, the fellewing (1121;511:1115 been rendered erjudgemem issued:
`DECISION/JUDG ELIENT
`
`Copy 1-----Upen initiation (11216111311, mail this eepy 11) Diree‘ter Cepy 3------ 151011 termination 01211111111, mzaii this cepy 1:11 Iiirecter
`{fem 2------Upon filing dewment adding patenfls), maifl this eepy 1:3 flireeter Cepy 4------Cause file cepy
`
`